芎芍胶囊治疗冠心病心绞痛临床疗效及安全性的系统评价  

Systematic Evaluation of the Effect and Safety of Xiongshao Capsules for the Treatment of Coronary Heart Disease Angina Pectoris

作　　者：张淼 许贵鹏 陈利捷 林宝虹[1] 吴正治[1] ZHANG Miao;XU Guipeng;CHEN Lijie;LIN Baohong;WU Zhengzhi(Shenzhen Second People's Hospital,Shenzhen 518000,Guangdong,China)

机构地区：[1]深圳市第二人民医院,广东深圳518000

出　　处：《中西医结合心脑血管病杂志》2024年第8期1354-1362,1394,共10页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家自然科学青年基金项目(No.82104770);广东省基础与应用基础研究基金项目(No.2022A1515011456)。

摘　　要：目的:系统评价芎芍胶囊治疗冠心病心绞痛的临床效果及安全性。方法:计算机检索Web of SCI、PubMed、EMbase、the Cochrane Library、万方数据资源系统(WanFang Database)、维普中文科技期刊全文数据库(VIP)、中国知网(CNKI)、中国生物医学文献服务系统(SinoMed)等数据库,纳入芎芍胶囊对比单独使用常规西药或血府逐瘀胶囊干预冠心病心绞痛的随机对照试验研究(RCT)。由2位评价者独立筛选提取文献资料、评定偏倚风险,使用RevMan 5.3进行Meta分析。结果:纳入12项研究,涉及1309例病人。Meta分析结果显示,试验组在提高临床总有效率[RR=1.17,95%CI(1.11,1.23),P<0.00001]、提高心电图疗效[RR=1.22,95%CI(1.09,1.36),P=0.0003]、降低三酰甘油(TG)[MD=-0.19,95%CI(-0.35,-0.04),P=0.02]、升高高密度脂蛋白胆固醇(HDL-C)[MD=0.13,95%CI(0.07,0.19),P<0.0001]方面均优于对照组,而两组在减低总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及不良反应发生率方面比较差异无统计学意义(P>0.05)。结论:现有证据表明,芎芍胶囊治疗冠心病心绞痛的临床效果明确,安全性较好。Objective:To evaluate the clinical effect and safety of Xiongshao Capsules for the treatment of coronary heart disease angina pectoris.Methods:Web of SCI,PubMed,EMbase,the Cochrane Library,WanFang data Resource System(WanFang Database),VIP Chinese Science and Technology Journal Ful-l text Database(VIP),CNKI,China Biomedical Literature Service System(SinoMed)and other databases were searched.The randomized controlled trials(RCT)of Xiongshao Capsules compared with conventional Western medicine or Xuefu Zhuyu Capsules intervention in the treatment of coronary heart disease angina pectoris were included.Two reviewers independently screened and extracted literature data to assess the risk of bias.RevMan 5.3 software was used for Meta-analysis.Result:A total of 12 literatures were included,including 1309 patients.Meta-analysis results showed that the experimental group the total clinical efficacy(RR=1.17,95%CI 1.11-1.23,P<0.00001),electrocardiogram effect(RR=1.22,95%CI 1.09-1.36,P=0.0003),and lipid triacylglycerol(TG)(MD=-0.19,95%CI-0.35--0.04,P=0.02)reduced and High density lipoprotein cholesterol(HDL-C)(MD=0.13,95%CI 0.07-0.19,P<0.0001)were better than that of control group.There was no significant difference in TC,LDL-C and adverse reactions between two groups(P>0.05).Conclusion:The current evidence showed that Xiongshao Capsules for the treatment of coronary heart disease angina pectoris with clear effect and better safety.

关 键 词：冠心病 心绞痛 芎芍胶囊 活血化瘀 系统评价 

分 类 号：R259[医药卫生—中西医结合]